SML2892
LY2584702 tosylate
≥98% (HPLC)
别名:
4-[4-[4-[4-Fluoro-3-(trifluoromethyl)phenyl]-1-methyl-1H-imidazol-2-yl]-1-piperidinyl]-1H-pyrazolo[3,4-d]pyrimidine, 4-methylbenzenesulfonate (1:1), LY 2584702 tosylate, LY 2779964, LY-2584702 tosylate, LY-2779964, LY2779964, LYS6K2 tosylate
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C21H19F4N7 · C7H8O3S
CAS号:
分子量:
617.62
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
2-8°C
SMILES字符串
FC(F)(F)c2c(ccc(c2)c3nc([n](c3)C)C4CCN(CC4)c5ncnc6n[nH]cc65)F.[S](=O)(=O)(O)c1ccc(cc1)C
InChI
1S/C21H19F4N7.C7H8O3S/c1-31-10-17(13-2-3-16(22)15(8-13)21(23,24)25)29-19(31)12-4-6-32(7-5-12)20-14-9-28-30-18(14)26-11-27-20;1-6-2-4-7(5-3-6)11(8,9)10/h2-3,8-12H,4-7H2,1H3,(H,26,27,28,30);2-5H,1H3,(H,8,9,10)
InChI key
HDYUXDNMHBQKAU-UHFFFAOYSA-N
生化/生理作用
LY2584702 is an orally active, ATP-competitive, potent and selective ribosomal protein S6 kinase (p70 S6 kinase, p70S6K, S6K1) inhibitor (IC50 = 4 nM; selective over 83 other kinases and 45 cell surface markers). LY2584702 inhibits HCT116 cellular S6 phosphorylation (IC50 0.1-0.24 μM) and shows anti-tumor efficacy in U87MG glioblastoma and HCT116 colon carcinoma xenograft models in vivo (2.5 mg/kg bid. po.).
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
从最新的版本中选择一种：
Anthony Tolcher et al.
European journal of cancer (Oxford, England : 1990), 50(5), 867-875 (2014-01-21)
LY2584702 tosylate (hereafter referred to as LY2584702) is a potent, highly selective adenosine triphosphate (ATP) competitive inhibitor against p70 S6 kinase, a downstream component of the phosphatidylinositol-3-kinase signalling pathway which regulates cell proliferation and survival. LY2584702 exhibited anti-tumour activity in
Anne-Sophie Archambault et al.
PloS one, 12(1), e0169804-e0169804 (2017-01-10)
LTB4 is an inflammatory lipid mediator mainly biosynthesized by leukocytes. Since its implication in inflammatory diseases is well recognized, many tools to regulate its biosynthesis have been developed and showed promising results in vitro and in vivo, but mixed results
Honyin Chiu et al.
Journal of immunology (Baltimore, Md. : 1950), 202(2), 579-590 (2018-12-12)
During an adaptive immune response, activated mature B cells give rise to Ab-secreting plasma cells to fight infection. B cells undergo Ab class switching to produce different classes of Abs with varying effector functions. The mammalian/mechanistic target of rapamycin (mTOR)
Valentina Romeo et al.
Journal of immunology (Baltimore, Md. : 1950), 203(1), 137-147 (2019-05-17)
PI3K is one of the most frequently mutated genes in cancers and has been the target of numerous anticancer therapies. With the additional development of therapeutics that mobilize the immune system, such as Abs with effector functions, bispecific Abs, and
Ming-Zhao Gao et al.
Acta pharmacologica Sinica, 40(2), 268-278 (2018-05-20)
BRAF and MEK inhibitors have shown remarkable clinical efficacy in BRAF-mutant melanoma; however, most patients develop resistance, which limits the clinical benefit of these agents. In this study, we found that the human melanoma cell clones, A375-DR and A375-TR, with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门